What do systematic reviews say?

Endovenous laser ablation (EVLA) vs radiofrequency ablation

• Interventions for great saphenous vein incompetence 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Very low

Endovenous laser ablation (EVLA) vs radiofrequency ablation

• Interventions for great saphenous vein incompetence 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Moderate

Endovenous laser ablation (EVLA) vs foam sclerotherapy

Endovenous laser ablation (EVLA) showed no clear difference in technical success (< 5 years) compared with ultrasound‐guided foam sclerotherapy (UGFS) (low certainty).

• Interventions for great saphenous vein incompetence 2021 · Cochrane Headline outcomes only
  OR 6.13 [0.98, 38.27]
  3 studies · 588 participants
  Low
• Interventions for great saphenous vein incompetence 2021 · Cochrane Headline outcomes only
  OR 6.47 [2.6, 16.1]
  3 studies · 534 participants
  Low

Endovenous laser ablation (EVLA) vs foam sclerotherapy

It is very uncertain whether endovenous laser ablation (EVLA) changes recurrence (< 5 years) compared with ultrasound‐guided foam sclerotherapy (UGFS) (very low certainty).

• Interventions for great saphenous vein incompetence 2021 · Cochrane Headline outcomes only
  OR 0.68 [0.2, 2.36]
  2 studies · 443 participants
  Very low

Nicotine replacement therapy vs placebo

Nicotine replacement therapy for smoking cessation showed no clear difference in mean weight change (kg) at end of treatment compared with placebo (moderate certainty).

• Interventions for preventing weight gain after smoking cessation 2021 · Cochrane Headline outcomes only
  MD 0.52
  21 studies · 2784 participants
  Moderate
• Interventions for preventing weight gain after smoking cessation 2021 · Cochrane Headline outcomes only
  MD 0.08
  11 studies · 1021 participants
  Moderate
• Interventions for preventing weight gain after smoking cessation 2021 · Cochrane Headline outcomes only
  MD 0.37
  17 studies · 1463 participants
  Moderate

Varenicline vs placebo

Varenicline for smoking cessation showed no clear difference in mean weight change (kg) at end of treatment compared with placebo (high certainty).

• Interventions for preventing weight gain after smoking cessation 2021 · Cochrane Headline outcomes only
  MD 0.23
  14 studies · 2566 participants
  High
• Interventions for preventing weight gain after smoking cessation 2021 · Cochrane Headline outcomes only
  MD 0.09
  3 studies · 384 participants
  Low
• Interventions for preventing weight gain after smoking cessation 2021 · Cochrane Headline outcomes only
  MD 1.05
  3 studies · 237 participants
  Low

Fluoexetine vs placebo

Fluoexetine showed no clear difference in mean weight change (kg) at end of treatment compared with placebo (low certainty).

• Interventions for preventing weight gain after smoking cessation 2021 · Cochrane Headline outcomes only
  MD 1.01
  2 studies · 144 participants
  Low
• Interventions for preventing weight gain after smoking cessation 2021 · Cochrane Headline outcomes only
  MD 1.01
  2 studies · 124 participants
  Very low

Intervention not reported

• Interventions for improving outcomes in patients with multimorbidity in primary care and community settings 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Moderate

Intervention not reported

• Interventions for improving outcomes in patients with multimorbidity in primary care and community settings 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  High

Intervention not reported

• Interventions for improving outcomes in patients with multimorbidity in primary care and community settings 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Moderate

Intervention not reported

• Interventions for improving outcomes in patients with multimorbidity in primary care and community settings 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Low

Intervention not reported

• Interventions for improving outcomes in patients with multimorbidity in primary care and community settings 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Low

Intervention not reported

• Interventions for improving outcomes in patients with multimorbidity in primary care and community settings 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Moderate

Intervention not reported

• Interventions for improving outcomes in patients with multimorbidity in primary care and community settings 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Moderate

Surgery for Bell's palsy vs medical treatment (oral prednisolone) or no treatment

It is very uncertain whether surgery for Bell's palsy changes complete recovery of facial nerve function at 12 months Defined as:… compared with medical treatment (oral prednisolone) or no treatment (very low certainty).

• Surgical interventions for the early management of Bell's palsy 2021 · Cochrane Headline outcomes only
  RR 0.76
  2 studies · 57 participants
  Very low

Surgery for Bell's palsy vs medical treatment (oral prednisolone) or no treatment

It is very uncertain whether surgery for Bell's palsy changes side effects and complications of treatmentMeasured by clinical… compared with medical treatment (oral prednisolone) or no treatment (very low certainty).

• Surgical interventions for the early management of Bell's palsy 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 57 participants
  Very low

Early surgery vs late surgery

It is very uncertain whether early surgery changes complete recovery of facial nerve function at 12 months Defined as:… compared with late surgery (very low certainty).

• Surgical interventions for the early management of Bell's palsy 2021 · Cochrane Headline outcomes only
  RR 0.47 [0.03, 6.6]
  1 study · 26 participants
  Very low

Early surgery vs late surgery

• Surgical interventions for the early management of Bell's palsy 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 26 participants
  GRADE not reported

Oral methotrexate vs placebo

Oral methotrexate may leads to higher primary outcome: complete clinical response (malar/discoid rash) compared with placebo (low certainty).

• Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes only
  RR 3.57 [1.63, 7.84]
  1 study · 41 participants
  Low

Oral hydroxychloroquine vs placebo

Oral hydroxychloroquine probably leads to lower secondary outcome: clinical flare compared with placebo (moderate certainty).

• Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes only
  RR 0.49 [0.28, 0.89]
  1 study · 47 participants
  Moderate